BG103251A - Oxydiazols, methods for their preparation and application as medicamentous forms - Google Patents

Oxydiazols, methods for their preparation and application as medicamentous forms

Info

Publication number
BG103251A
BG103251A BG103251A BG10325199A BG103251A BG 103251 A BG103251 A BG 103251A BG 103251 A BG103251 A BG 103251A BG 10325199 A BG10325199 A BG 10325199A BG 103251 A BG103251 A BG 103251A
Authority
BG
Bulgaria
Prior art keywords
preparation
methods
application
oxydiazols
medicamentous forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BG103251A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Brenner
Roland Maier
Marion Wienrich
Thomas Weiser
Rainer Palluk
Wolf-Dietrich Bechtel
Angelo Sagrada
Helmut Ensinger
Uwe Pschorn
Raffaele Cesana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BG103251A publication Critical patent/BG103251A/xx
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BG103251A 1996-10-18 1999-03-15 Oxydiazols, methods for their preparation and application as medicamentous forms Pending BG103251A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19643037A DE19643037A1 (de) 1996-10-18 1996-10-18 Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
PCT/EP1997/005693 WO1998017652A1 (fr) 1996-10-18 1997-10-15 Oxadiazoles, procedes permettant de les preparer et leur utilisation comme medicaments

Publications (1)

Publication Number Publication Date
BG103251A true BG103251A (en) 2000-02-29

Family

ID=7809114

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103251A Pending BG103251A (en) 1996-10-18 1999-03-15 Oxydiazols, methods for their preparation and application as medicamentous forms

Country Status (32)

Country Link
US (1) US6277872B1 (fr)
EP (1) EP0934288B1 (fr)
JP (1) JP3333523B2 (fr)
KR (1) KR20000049253A (fr)
CN (1) CN1086698C (fr)
AR (1) AR008496A1 (fr)
AT (1) ATE315034T1 (fr)
AU (1) AU737552B2 (fr)
BG (1) BG103251A (fr)
BR (1) BR9714354A (fr)
CA (1) CA2268954C (fr)
CO (1) CO4920253A1 (fr)
CZ (1) CZ138099A3 (fr)
DE (2) DE19643037A1 (fr)
EE (1) EE9900147A (fr)
ES (1) ES2256880T3 (fr)
HK (1) HK1020956A1 (fr)
HR (1) HRP970553A2 (fr)
HU (1) HUP0001652A3 (fr)
ID (1) ID18613A (fr)
IL (1) IL129315A0 (fr)
NO (1) NO312512B1 (fr)
NZ (1) NZ335598A (fr)
PE (1) PE11199A1 (fr)
PL (1) PL332432A1 (fr)
RU (1) RU2182905C2 (fr)
SK (1) SK49999A3 (fr)
TR (1) TR199900848T2 (fr)
TW (1) TW413678B (fr)
WO (1) WO1998017652A1 (fr)
YU (1) YU40997A (fr)
ZA (1) ZA979220B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816880A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
IT1300056B1 (it) 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
DE60027546T2 (de) 1999-02-15 2007-04-26 Eisai Co., Ltd. Heterodiazinon-derivate
PT1070708E (pt) 1999-07-21 2004-05-31 Hoffmann La Roche Derivados de triazol
EP1582519A3 (fr) * 1999-08-19 2005-12-21 Nps Pharmaceuticals, Inc. Composes heteropolycycliques et leur utilisation comme antagonistes des recepteurs glutamiques metabotropes
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ES2250177T3 (es) * 1999-08-19 2006-04-16 Nps Pharmaceuticals, Inc. Compuestos heteropoliciclicos y su uso como antagonistas de receptores de glutamato metabotropico.
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
EP2177520A1 (fr) 2000-06-12 2010-04-21 Eisai R&D Management Co., Ltd. 1,5-Di(aryl ou hétéroaryl)-3-halo-2(1H)-pyridones comme intermédiaires pour la préparation d'inhibiteurs du récepteur AMPA
AU2001290229B2 (en) * 2000-09-18 2006-12-07 Eisai R&D Management Co., Ltd. Pyridazinones and triazinones and medicinal use thereof
IL157491A0 (en) * 2001-02-21 2004-03-28 Nps Pharmeceuticals Inc Heteropolycyclic compounds and pharmaceutical compositions containing the same
WO2003029210A2 (fr) * 2001-10-04 2003-04-10 Merck & Co. Inc. Composes de tetrazole substitues par heteroaryle, modulateurs du recepteur-5 metabotropique du glutamate
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
EP1530569A2 (fr) 2002-08-23 2005-05-18 Rigel Pharmaceuticals, Inc. Heterocycles a substitution pyridyle utiles dans le traitement de l'infection par le virus de l'hepatite c
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
WO2004099164A1 (fr) * 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Diphenyl isoxazoles, pyrazoles et oxadiazoles substitues, destines au traitement d'une infection par le vhc
US7326790B2 (en) 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
WO2005049065A2 (fr) 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Combinaisons efficaces d'un point de vue synergique de composes dihaloacetamide et d'interferon ou de ribavirine contre les infections par le virus de l'hepatite c (vhc)
CA2549955A1 (fr) 2003-12-24 2005-07-07 Prosidion Limited Derives heterocycliques utilises comme agonistes des recepteurs gpcr
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
JPWO2006109876A1 (ja) * 2005-04-08 2008-11-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 不随意運動治療剤
EP1883633A2 (fr) 2005-05-02 2008-02-06 Rigel Pharmaceuticals, Inc. Composes heterocycliques antiviraux comprenant des groupes metabolisables et leurs utilisations
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
MX2009006304A (es) * 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
US20110207704A1 (en) * 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
WO2009043890A1 (fr) * 2007-10-04 2009-04-09 Merck Serono S.A. Composés oxadiazole diarylés
US9045442B2 (en) * 2007-12-21 2015-06-02 University Of Notre Dame Du Lac Antibacterial compounds and methods of using same
TR201904041T4 (tr) 2008-06-09 2019-04-22 Max Planck Gesellschaft Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
WO2011047129A1 (fr) 2009-10-15 2011-04-21 Southern Research Institute Traitement de maladies neurodégénératives, cause d'amélioration de la mémoire et analyse pour évaluer des composés associés
AU2013305663B2 (en) * 2012-08-24 2017-11-02 Treventis Corporation Benzofurazan anti-amyloid compounds and methods
ES2734432T3 (es) 2014-02-27 2019-12-05 Treventis Corp Compuestos antiamiloides que contienen benzofurazano
US9884858B2 (en) 2014-04-24 2018-02-06 Sumitomo Chemical Company, Limited Diaryl-azole compound
US10662164B2 (en) 2014-09-25 2020-05-26 University Of Notre Dame Du Lac Non-beta lactam antibiotics
CN107286174B (zh) * 2016-04-11 2020-08-18 上海勋和医药科技有限公司 取代2,4-(1h,3h)嘧啶二酮作为parp抑制剂及其应用
WO2018049404A1 (fr) 2016-09-12 2018-03-15 University Of Notre Dame Du Lac Composés pour le traitement d'une infection par clostridium difficile
US11180518B2 (en) 2017-05-12 2021-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
MX2021006317A (es) 2018-12-14 2021-08-11 Eisai R&D Man Co Ltd Formulaciones farmaceuticas de base acuosa de compuestos de 1,2-dihidropiridina.
WO2023042888A1 (fr) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Composition pharmaceutique destinée à être mise en œuvre dans le traitement soit du déclin des fonctions cognitives, soit de la surcharge pondérale ou de l'obésité
WO2023042887A1 (fr) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Composition pharmaceutique destinée à être mise en œuvre dans le traitement soit du déclin des fonctions cognitives, soit de la surcharge pondérale ou de l'obésité
EP4173485A1 (fr) 2021-10-27 2023-05-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composés inhibant l'agrégation de protéine pour la lutte contre les maladies des plantes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
JPS52272A (en) * 1975-10-17 1977-01-05 Takeda Chem Ind Ltd Process for preparing 1,2,4-oxadiazole derivatives
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
JPS58150576A (ja) * 1982-03-03 1983-09-07 Sumitomo Chem Co Ltd 新規な1,2,4−オキサジアゾ−ル誘導体
US4871753A (en) * 1986-12-12 1989-10-03 Ciba-Geigy Corporation 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
JPH02250873A (ja) * 1989-03-24 1990-10-08 Mitsubishi Petrochem Co Ltd 1,2,4―オキサジアゾール誘導体及びそれを有効成分とする除草剤
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DK443489D0 (da) * 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
JPH04295470A (ja) * 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−b酵素阻害活性を有する1,2,4−オキサジアゾール誘導体及びその製造法
EP0596933A1 (fr) * 1991-08-03 1994-05-18 Smithkline Beecham Plc Antagonistes du recepteur 5-ht4
DE4401108A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 1,2,4-Oxadiazol-Derivate
DE4401107A1 (de) * 1994-01-17 1995-07-20 Bayer Ag 3-Aryl-alkenyl-1,2,4-oxadiazol-Derivate
DE19528189A1 (de) * 1995-08-01 1997-02-06 Basf Ag Benzolderivate mit einem heterocyclischen Rest

Also Published As

Publication number Publication date
CA2268954C (fr) 2006-06-13
JP3333523B2 (ja) 2002-10-15
EP0934288A1 (fr) 1999-08-11
YU40997A (sh) 2000-10-30
NO991815D0 (no) 1999-04-16
CN1086698C (zh) 2002-06-26
ES2256880T3 (es) 2006-07-16
NO312512B1 (no) 2002-05-21
HUP0001652A3 (en) 2002-12-28
CN1233245A (zh) 1999-10-27
SK49999A3 (en) 1999-11-08
ATE315034T1 (de) 2006-02-15
IL129315A0 (en) 2000-02-17
RU2182905C2 (ru) 2002-05-27
HRP970553A2 (en) 1998-08-31
PE11199A1 (es) 1999-03-03
TR199900848T2 (xx) 1999-06-21
KR20000049253A (ko) 2000-07-25
EE9900147A (et) 1999-12-15
AU4867697A (en) 1998-05-15
CZ138099A3 (cs) 1999-11-17
BR9714354A (pt) 2000-04-11
PL332432A1 (en) 1999-09-13
AR008496A1 (es) 2000-01-19
DE19643037A1 (de) 1998-04-23
EP0934288B1 (fr) 2006-01-04
NO991815L (no) 1999-04-16
HK1020956A1 (en) 2000-05-26
NZ335598A (en) 2001-06-29
AU737552B2 (en) 2001-08-23
CO4920253A1 (es) 2000-05-29
JP2000505089A (ja) 2000-04-25
DE59712543D1 (de) 2006-03-30
ZA979220B (en) 1998-04-20
HUP0001652A2 (hu) 2001-01-29
CA2268954A1 (fr) 1998-04-30
TW413678B (en) 2000-12-01
US6277872B1 (en) 2001-08-21
WO1998017652A1 (fr) 1998-04-30
ID18613A (id) 1998-04-23

Similar Documents

Publication Publication Date Title
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
BG101194A (en) New heteroaryl oxazolidinons
BG103590A (en) Pesticide 1-arylpyrazols
DE58906377D1 (en) Difluormethylverbindungen.
BG103413A (en) Derivatives of sulphinic acid, their production and application
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
IL130260A (en) 3-thiocarbamoylpyrazole derivatives as pesticides
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
MX9700557A (es) Dihidrobenzofuranos.
CA2276455A1 (fr) Phthalazinones
EP0900083A4 (fr) Nouveaux composes d'imidazole substitues
PL327934A1 (en) Novel substituted imidazole compounds
CA2297911A1 (fr) 6-phenylphenanthridines substitues
BG101110A (en) Substituted pyrimidine compounds and their application
PL338339A1 (en) Novel derivatives of tetrazole
BG103096A (en) Thrombin inhibitors
BG101105A (en) Substituted benzamidines, their preparation and application as medicamentous forms
BG102623A (en) New derivatives of benzoylguanadine, methods for their preparation and application for the manufacture of medicamentous forms
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
BG102395A (en) New phenylamidine derivatives, method for their preparation and application as medicamentous forms
BG102770A (en) New derivatives of carboxylic acids, their preparation and application
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
GB2324091A (en) Metalloproteinase inhibitors